Updated 07:15 GMT, 18 Nov 2026 SPX 7,340.53 -1.03% NDX 27,001.78 -0.72% VIX 25.46 +11.13% GOLD 3,772.20 -2.38% CL 83.98 -2.36% BTC 64,721.99 -0.26%
NAS100 27,002 −0.72% S&P 7,341 −1.03% GOLD $3,772 −2.38% BTC $64,722 −0.26% VIX 25.46 +11.13% latest tape · as of 07:15 UTC
The Screen · Healthcare · Medical Devices

Alamar Biosciences, Inc.

ALMR · Nasdaq · USD · Market cap $1.9B · 222 employees

Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases.

PASS · Titan Ethical · score 70.0
30.64 USD

Price as of 17 Nov 2026Daily close, not a live quote

Screened 2026-11-17 · the tape above runs as of 07:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price30.64 USD at the 17 Nov 2026 close
  • Our value readUndervalued vs our fair value, as of 17 Nov 2026
  • Our regime readMarkup, as of 16 Nov 2026
  • Ethical screenPasses, score 70.0 out of 100
  • Last reviewed17 Nov 2026 (1 day ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: $31.00 to $45.00, base estimate $34.00 (screen dated 2026-11-17).

Current read
Markup ?
Undervalued · screened 2026-11-17
  • Trend Markup
  • Insiders insiders sold, $2,941,571, latest filing 2026-11-11
  • Positioning no disclosures inside 60 days, left as found
  • Options no verdict drawn today, left as found
  • Ethical passes the values gate
Price30.64 USD
Fair value34.00
Ethical score70.0/100
Value readUndervaluedas of 17 Nov 2026
Our investment reviews on this name
2026-11-10Read Markup31.84-3.8% to today Distribution gives way to Markup after a 10% rise in 7 days
2026-11-03Read Distribution28.94+5.9% to today Markup gives way to Distribution after a 16% slide in 5 days
2026-10-29Read Markup34.30-10.7% to today Distribution gives way to Markup after a 15% rise in 2 days
2026-10-27Read Distribution29.72+3.1% to today Markup gives way to Distribution first Distribution read since October

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its markup label.

Alamar Biosciences, Inc. holds its Markup at $30.64. Elevated stress, defensive posture warranted, held for 12 days.

As held on the ledger · 2026-11-17
PhaseMarkup
Quantitative stateElevated stress, defensive posture warranted, held for 12 days
Price at the screen$30.64
ValuationN/A trailing · -64.72 forward price to earnings
Values screenPASS · score 70.0
The Workings

Five Screens, Shown in Full

Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.

TestFigureLimitWhat it meansStatus
Business activity Permissible Core business clean Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
Debt load 29.63% Below 33% Interest-bearing debt is just 29.6% of its assets, well under the one-third ceiling: it does not run on borrowed money. Pass
Interest-bearing cash 0.00% Below 33% Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. Pass
Receivables 30.54% Below 49% Money owed to the company is 30.5% of assets, under the 49% limit. Pass
Revenue purity 2.91% Below 5% Only 2.9% of revenue comes from non-compliant sources, under the 5% line. Pass

Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.

The Ethical Read

Why It Clears, in Plain English

Alamar Biosciences, clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 30%, inside the ~33% line, and interest is about 3% of its income, under the ~5% line, so it passes.

Read as at 2026-11-17. It updates when the underlying figures move, and past reads are kept below.

Follow this verdict

Get an email when ALMR's ethical verdict changes

Today ALMR passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Our analysis reads Undervalued vs our fair value, as of 17 Nov 2026: it trades at roughly a 10% discount to our $34.00 fair value, 68.50% revenue growth.

How a fair value is estimated: discounted cash flow (DCF).

31.00Conservative34.00Base case45.00Growth case 30.64Price

Fair value range in USD, drawn from the 2026-11-17 screen. The gold marker is the market price at the same screen. A 9.9% discount to the base estimate.

The Street's Range
31.00Street low 34.00Street average 45.00Street high 30.64Price

Third-party analyst targets. The average target sits +11% from the screen price.

Reading the gap · Both our model and the analysts see meaningful upside from here.

Price History & Projections

Where our models see it going: fair-value estimate $34.00, with a range of $31.00 to $45.00, dated to the 2026-11-17 screen.

Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.

The Business, in Plain Words

Early disease detection sounds promising but stays unproven

Imagine a blood test that spots disease proteins years before symptoms appear. Alamar Biosciences is racing to build that with its NULISA platform, selling instruments and consumables into a market hungry for better diagnostics. Revenue is doubling each year at 99 percent, the shares trade below our calculated fair value, and the business clears our ethical screen without issue.

Yet the numbers still give pause. Margins sit at minus 50 percent, the forward multiple is deeply negative, and no clear moat protects the technology from larger rivals. Five analysts call it a buy with a 32 dollar median target, but that optimism rests on forecasts that have yet to turn into sustained profits.

High growth in medical tools often masks how long it takes to reach scale and steady cash flow. We therefore pass. Analysis, not advice.

The fundamentals · plain-English read
Forward P/E-64.7x
EPS, trailing-1.13
EPS, forward-0.42
Revenue growth+68.5%growing very fast
Profit margin-48.2%currently unprofitable
Debt to equity0.14minimal debt: a conservative balance sheet
Current ratio9.49comfortably covers its short-term bills
Short interest, float0.06%
52-week range18.85 - 39.61
Market cap$1.9B
Employees222

Another profit measure, before interest, tax and non-cash costs: EBITDA.

The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.

Plain-English interpretation of our own screen data. Analysis, not advice.

Where & How to Trade

ALMR trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-10 Markup · changed $31.84 +10.0% Entry 13

The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 10.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading neutral. The street (5 analysts) rates it none, with a mean price target of $30. Insiders have been net sellers over the past quarter. Since the last review it its composite score rose.

2026-11-03 Distribution · changed $28.94 -5.4% Entry 12

The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 5.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bearish. The street (5 analysts) rates it none, with a mean price target of $30. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-02 Markup $30.60 +0.0% Entry 11

The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bearish. The street (5 analysts) rates it none, with a mean price target of $30. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-01 Markup $30.60 +0.0% Entry 10

The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bearish. The street (5 analysts) rates it none, with a mean price target of $30. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-31 Markup $30.60 -10.1% Entry 9

The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 10.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bearish. The street (5 analysts) rates it none, with a mean price target of $30. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-30 Markup $34.04 -0.8% Entry 8

The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bearish. The street (5 analysts) rates it none, with a mean price target of $30. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-29 Markup · changed $34.30 +15.4% Entry 7

The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 15.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bearish. The street (5 analysts) rates it none, with a mean price target of $30. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-28 Distribution $29.72 +0.0% Entry 6

The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bearish. The street (5 analysts) rates it none, with a mean price target of $30. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-27 Distribution · changed $29.72 +0.0% Entry 5

The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bearish. The street (5 analysts) rates it none, with a mean price target of $30. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-23 Markup · changed $29.72 -7.9% Entry 4

The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 7.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading bearish. The street (5 analysts) rates it none, with a mean price target of $30. Insiders have been net sellers over the past quarter.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

Latest News · What the Market Is Reading on ALMR

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in ALMR's Space

Screened names in the same industry · explore each on its own page.

The Insider Ledger · Form 4 Filings, As Filed
Most recent filings · ALMR
DateInsiderTitleTypeSharesValue
2026-11-11 Qiming Corporate Gp Vi, Ltd. 10% S - Sale 100,117 $2,941,571
2026-10-27 Qiming Corporate Gp Vi, Ltd. 10% S - Sale 185,731 $5,968,888
2026-10-23 Qiming Corporate Gp Vi, Ltd. 10% S - Sale 280,458 $8,569,760
2026-10-21 Qiming Corporate Gp Vi, Ltd. 10% S - Sale 342,626 $10,253,095
2026-10-15 Qiming Corporate Gp Vi, Ltd. 10% S - Sale 173,673 $4,816,121

Public filings, recorded as found. The full tape lives at Insider Intelligence.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $23.88 -10.5% · $895 -10.5%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever ALMR does next, these words stay.

Alamar Biosciences, Inc. · ALMR · Markup · $30.64
Recorded 2026-11-17 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.